Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
News|Articles|September 1, 2016
DCAT Launches Networking Event in Barcelona
Author(s)Pharmaceutical Technology Editors
Organization plans networking event at CPhI Worldwide to serve expanding global membership.
Advertisement
The Drug, Chemical & Associated Technologies Association (DCAT) has announced a networking event,DCAT After The Show, at Casa Llotja de Mar in Barcelona, Spain on Oct. 5, 2016 from 6–8:30 pm. The event is scheduled following the second day of activities at CPhI Worldwide.
“With the growth of the organization’s membership globally, the DCAT leadership expanded the networking opportunities for members who may not attend DCAT Week, our flagship event held annually in New York City,” said DCAT President Dr. Folker Ruchatz, Corporate Vice President, Consumer Health Care Operations and Third Party Management at Boehringer Ingelheim GmbH. The organization noted that nearly half of new member companies located outside North America.
Source:
Advertisement
Related to this article
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
This article discusses risk-based lifecycle governance, system implementation considerations, and the progression of batch record control from paper-based to fully electronic systems.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Tavapadon Sets Development Benchmark for Parkinson's
2
KRAS G12D Inhibitor's $2.13B Deal Tests Cross-Border Tech Transfer
3
Weekly Basal Insulin Efsitora: A New Biologics CMC Benchmark
4
PharmTech’s Weekly Roundup—September 25, 2026
5